Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7959)	11/10/2000 7:34:16 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

Protein families are certainly the core of AxCell Biosciences Corp.'s business strategy. And, the Princeton, NJ subsidiary of Cytogen Corp. intends to sell defined sets of known protein families, as arrays, for use in lead optimization in drug discovery programs. It's building an inter-functional proteomic database of human protein signaling pathways, which can be used to correlate protein pathway data with sequence, expression, tissue distribution, structural and bibliographic information that exists for that particular protein and pathway. To measure protein interactions on a chip, AxCell recently joined forces with privately held Molecular Staging Inc. MSI, of Guilford, CT, brings to the alliance its rolling circle amplification technology, a nucleic acid amplification technology for detecting the presence of target molecules arrayed on a chip. Parent company Cytogen already has a separate, ongoing collaboration with MSI to develop ultra-sensitive diagnostic assays for prostate cancer; according to John Rodwell, AxCell's acting president and chief technical officer, the companies have already initiated work on protein chip technology. Now, they intend to develop that into a high-throughput technology for measuring protein-protein interactions.... signalsmag.com